Sanofi said to be near $11.5 billion deal to buy Bioverativ
January 21, 2018 at 20:54 PM EST
Sanofi SA is nearing a deal to buy hemophilia drugmaker Bioverativ Inc. for more than $11.5 billion as the French drugmaker looks set to clinch a big deal while it braces for generic competition for its top-selling product.